Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Net Income towards Common Stockholders (2016 - 2020)

Historic Net Income towards Common Stockholders for Phio Pharmaceuticals (PHIO) over the last 9 years, with Q4 2020 value amounting to -$2.5 million.

  • Phio Pharmaceuticals' Net Income towards Common Stockholders rose 775.57% to -$2.5 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$2.5 million, marking a year-over-year increase of 7264.44%. This contributed to the annual value of -$11.5 million for FY2022, which is 1359.98% up from last year.
  • As of Q4 2020, Phio Pharmaceuticals' Net Income towards Common Stockholders stood at -$2.5 million, which was up 775.57% from -$2.3 million recorded in Q3 2020.
  • Phio Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$1.5 million during Q3 2018, with a 5-year trough of -$5.5 million in Q1 2017.
  • In the last 5 years, Phio Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$2.2 million in 2016 and averaged -$2.4 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 14473.33% in 2017, then surged by 5899.27% in 2018.
  • Quarter analysis of 5 years shows Phio Pharmaceuticals' Net Income towards Common Stockholders stood at -$4.4 million in 2016, then surged by 54.64% to -$2.0 million in 2017, then grew by 13.74% to -$1.7 million in 2018, then crashed by 54.55% to -$2.7 million in 2019, then increased by 7.76% to -$2.5 million in 2020.
  • Its last three reported values are -$2.5 million in Q4 2020, -$2.3 million for Q3 2020, and -$1.7 million during Q2 2020.